ECSP088816A - Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismos - Google Patents

Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismos

Info

Publication number
ECSP088816A
ECSP088816A EC2008008816A ECSP088816A ECSP088816A EC SP088816 A ECSP088816 A EC SP088816A EC 2008008816 A EC2008008816 A EC 2008008816A EC SP088816 A ECSP088816 A EC SP088816A EC SP088816 A ECSP088816 A EC SP088816A
Authority
EC
Ecuador
Prior art keywords
insulin
receiver
similar
same
growth factor
Prior art date
Application number
EC2008008816A
Other languages
English (en)
Inventor
Klaus-Peter Kuenkele
Ralf Schumacher
Silke Hansen
Dietmar Reusch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088816(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088816A publication Critical patent/ECSP088816A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo que se fija sobre el IGF-IR, es del tipo IgG1 o IgG3 humano y está glucosilado con una cadena azúcar en Asn297, dicho anticuerpo está caracterizado porque la cantidad de fucosa dentro de dicha cadena azúcar es por lo menos del 99% y además la cantidad de NGNA es del 1% o menos y/o la cantidad de alfa-1,3-galactosa del extremo N es del 1% o menos, tiene propiedades mejoradas para la terapia antitumoral.
EC2008008816A 2006-04-11 2008-10-09 Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismos ECSP088816A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11

Publications (1)

Publication Number Publication Date
ECSP088816A true ECSP088816A (es) 2008-11-27

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008816A ECSP088816A (es) 2006-04-11 2008-10-09 Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismos

Country Status (20)

Country Link
US (1) US20080014203A1 (es)
EP (2) EP2363417A1 (es)
JP (1) JP4718634B2 (es)
KR (2) KR101276513B1 (es)
CN (1) CN101421305B (es)
AR (1) AR060592A1 (es)
AU (1) AU2007236199B2 (es)
BR (1) BRPI0710185B8 (es)
CA (2) CA2647181C (es)
CR (1) CR10301A (es)
EC (1) ECSP088816A (es)
ES (1) ES2403075T3 (es)
IL (1) IL194397A (es)
MX (1) MX2008012950A (es)
NO (1) NO20084082L (es)
NZ (1) NZ571414A (es)
RU (1) RU2541765C2 (es)
UA (1) UA95284C2 (es)
WO (1) WO2007115814A2 (es)
ZA (1) ZA200808597B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2225273B1 (en) 2007-12-21 2012-05-23 Roche Glycart AG Stability testing of antibodies
EA029178B1 (ru) 2008-12-12 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против инсулиноподобных факторов роста, молекула днк, вектор, клетка-хозяин, предназначенные для получения этого антитела, способ его получения и применение
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CA2766836A1 (en) 2009-07-24 2011-01-27 F. Hoffmann-La Roche Ag Stirrer system
US9056907B2 (en) 2009-10-07 2015-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (IGF) system
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
RU2591523C2 (ru) 2010-11-05 2016-07-20 Ф. Хоффманн-Ля Рош Аг Оптимизированный метод захвата антител хроматографией смешанного типа
ES2667864T3 (es) 2011-06-22 2018-05-14 F. Hoffmann-La Roche Ag Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
MX361076B (es) 2012-12-21 2018-11-27 Hoffmann La Roche Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021119234A1 (en) * 2019-12-10 2021-06-17 Horizon Pharma Ireland Ltd. Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
CA2704600C (en) * 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
JP4563171B2 (ja) * 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
US7378503B2 (en) * 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
WO2005014651A1 (ja) * 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
US8603481B2 (en) * 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors

Also Published As

Publication number Publication date
ZA200808597B (en) 2009-11-25
UA95284C2 (ru) 2011-07-25
ES2403075T3 (es) 2013-05-13
CN101421305A (zh) 2009-04-29
EP2363417A1 (en) 2011-09-07
AU2007236199B2 (en) 2013-07-25
RU2541765C2 (ru) 2015-02-20
KR101276513B1 (ko) 2013-06-21
BRPI0710185B8 (pt) 2021-05-25
WO2007115814A2 (en) 2007-10-18
IL194397A0 (en) 2011-08-01
IL194397A (en) 2014-04-30
NO20084082L (no) 2008-11-06
BRPI0710185A8 (pt) 2019-01-22
AR060592A1 (es) 2008-07-02
EP2007810A2 (en) 2008-12-31
JP2009533367A (ja) 2009-09-17
EP2007810B1 (en) 2013-02-13
BRPI0710185B1 (pt) 2020-01-14
CR10301A (es) 2008-10-29
NZ571414A (en) 2011-12-22
AU2007236199A1 (en) 2007-10-18
MX2008012950A (es) 2008-10-15
RU2008144290A (ru) 2010-05-20
KR20080113233A (ko) 2008-12-29
JP4718634B2 (ja) 2011-07-06
BRPI0710185A2 (pt) 2011-08-09
CA2647181A1 (en) 2007-10-18
CA2647181C (en) 2020-08-11
WO2007115814A3 (en) 2008-01-10
US20080014203A1 (en) 2008-01-17
CN101421305B (zh) 2013-05-15
CA3081707A1 (en) 2007-10-18
KR20120028396A (ko) 2012-03-22

Similar Documents

Publication Publication Date Title
ECSP088816A (es) Anticuerpos contra el receptor del factor de crecimiento i similar a la insulina y usos de los mismos
ECSP088814A (es) Anticuerpos fucosilados
CR10810A (es) Anticuerpos contra el receptor del factor de crecimiento similar a la insulina i y la utilizacion de los mismos
CL2008003788A1 (es) Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20.
UY32764A (es) Preparaciones insulinicas que comprenden metionina
CL2012000391A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina.
CL2007002667A1 (es) Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.
GT200600046A (es) Terapia de combinacion
AR079333A1 (es) Anticuerpos contra csf -1r humano y usos de los mimos
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
PE20081899A1 (es) Anticuerpos anti-ige
AR033439A1 (es) Composicion que comprende adyuvante prebiotico para disminuir procesos inflamatorios y activacion anormal de parametros no especificos inmunitarios
PE20121063A1 (es) Anticuerpos anti-cdcp1 humanizados
MX358013B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
CL2007002841A1 (es) Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina.
WO2006115800A3 (en) Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CO6321157A2 (es) Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo
ITRM20080529A1 (it) Uso della l-chinurenina e suoi derivati per la prevenzione ed il trattamento del diabete mellito di tipo 1.
WO2009108168A3 (en) Gold nanoparticle glycoconjugates for generating igg specific for the carbohydrate
UY30616A1 (es) Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
AR086738A1 (es) Uso de un anticuerpo anti-cd20 de gran citotoxicidad para la mediacion celular dependiente de anticuerpos (adcc) en el tratamiento de la enfermedad de waldenström
MD201Y (en) Medium for cryoconservation of human sperm
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13